{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Screeningb', 'C1', 'C1', 'MM Disease', 'In-clinic Dosing', 'EoT', 'Safety', 'Durability of', 'Phone Call', 'Assessment', 'Visits', 'Visit', 'Follow-', 'Response and', 'Visits', '(> C1D2)', 'up Call', 'Survival', '(Table 13)', '(Table 13)', 'Follow-up', 'Visit', 'D-28 to -1', 'D1e', 'D3f', 'See Table 4,', 'See Table 4,', '14', '30 days', 'Every', '(selinexor-', 'Table 5,', 'Table 5,', 'Days', 'after last', '3 months', 'containing', 'Table 6, and', 'Table 6, and', 'Post-', 'dose of', 'until', 'regimens', 'Table 7', 'Table 7', 'Last', 'treatment', 'End-of-Study', 'only)', 'Dose', 'Section 11.7.4', 'Activity/Assessment', 'Section', '2 daysg', '2 days', '+ 7 days', '14 days', 'Multiple Myeloma Disease Assessments', 'SPEP with serum', 'protein', '11.3.1.1', 'X', 'X', 'X', 'X', 'X', 'immunofixations', 'UPEP (24-hr urine)', 'and urine protein', '11.3.1.2', 'X', 'X', 'X', 'X', 'X', 'immunofixations', 'Quantitative Ig levels', '11.3.1.3', 'X', 'X', 'X', 'X', 'X', \"Serum FLC's\", '11.3.1.4', 'X', 'X', 'X', 'X', 'X', '2-microglobulin', '11.3.1.5', 'X', 'X', 'LDH', '11.3.1.6', 'X\u00b0', 'X', 'Perform if', 'Skeletal surveyt', '11.3.1.7', 'X', 'Frequency determined by the', 'X', 'clinically', 'Investigator', 'indicated', 'Clinical', 'Perform if', 'Perform if', 'plasmacytoma', '11.3.1.8', 'X', 'X', 'clinically', 'X', 'clinically', 'assessment5,', 'indicated', 'indicated', 'Perform if', 'Bone marrow', '11.3.1.9', 'X', 'At the time of response for the MRD test for', 'clinically', 'aspirate', 'patients who achieve CR or sCR', 'indicated', 'Bone marrow core', '11.3.1.10', 'At the time of response to confirm CR or', '(trephine) biopsy\"', 'sCR', 'X', 'HR-QoLX', '11.6', 'X', '(D1 of each', 'X', 'cycle only)', 'Randomization', '8.2', 'Prior to dosing of Vd/SVd', 'Confidential', 'Page 24', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Screeningb', 'C1', 'C1', 'MM Disease', 'In-clinic Dosing', 'EoT', 'Safety', 'Durability of', 'Phone Call', 'Assessment', 'Visits', 'Visit', 'Follow-', 'Response and', 'Visits', '(> C1D2)', 'up Call', 'Survival', '(Table 13)', '(Table 13)', 'Follow-up', 'Visit', 'D-28 to -1', 'D1e', 'D3t', 'See Table 4,', 'See Table 4,', '14', '30 days', 'Every', '(selinexor-', 'Table 5,', 'Table 5,', 'Days', 'after last', '3 months', 'containing', 'Table 6, and', 'Table 6, and', 'Post-', 'dose of', 'until', 'regimens', 'Table 7', 'Table 7', 'Last', 'treatment', 'End-of-Study', 'only)', 'Dose', 'Section 11.7.4', 'Activity/Assessment', 'Section', '2 days', '2 days', '+ 7 days', '14 days', 'See', 'Table 8', 'See Table 4,', 'Table 4,', 'See Table 4,', 'Administration of', 'Table 9', 'Table 5,', 'Table 5,', 'Table 5, Table 6,', 'study treatment', 'Table 10', 'Table 6, and', 'Table 6,', 'and Table 7y', 'Table 11', 'Table 7', 'and Table 7', 'AE recording', '12.1.2', 'Throughout', 'SAE reporting', '12.2.3', 'Throughout', 'Concomitant', '11.5.1.5', 'Throughout', 'medication recording', 'Nutritional', '11.7.2', 'Xm', 'consultation', 'Telephone contact', '11.7.3', 'Xf', 'X', 'Collection of', 'information regarding', '11.7.1', 'X', 'X', 'antineoplastic therapy', 'used after EoT', 'Abbreviations: AE = adverse event; BP = blood pressure; BSA = body surface area; CBC = complete blood count; CR = complete response; CT = computed', 'tomography;', 'C1D1 = Cycle 1 Day 1; D = day; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; EORTC = European Organization for Research and Treatment of', 'Cancer; EoT = end of treatment:', '; FISH = fluorescence in situ hybridization; FLC = free light chain; hCG = human chorionic', 'gonadotropin; hr = hour; ICF = informed consent form; HR-QoL = health-related quality of life; Ig = immunoglobulin; IMWG = International Myeloma Working Group;', 'IRC = Independent Review Committee; LDH = lactate dehydrogenase; MM = multiple myeloma; MRD = minimal residual disease; PD = progressive disease;', 'PDn = pharmacodynamics; PE = physical examination; PET = positron emission tomography; PK = pharmacokinetics;', 'QLQ-CIPN20 = Chemotherapy-induceo Peripheral Neuropathy instrument; SAE = serious adverse event; sCR = stringent complete response; SdX = selinexor plus low-dose', 'dexamethasone treatment after crossover; SPEP = serum protein electrophoresis; SVd = selinexor plus bortezomib plus low-dose dexamethasone; SVdX = SVd treatment after', 'crossover; UPEP = urine protein electrophoresis; Vd = bortezomib plus low-dose dexamethasone.', 'a If study treatment is administered on a visit day, the assessments for that visit should be performed before study treatment is administered.', 'b', 'Procedures that are performed as part of standard of care should not be repeated if they are within the Screening window and are done prior to signing the ICF.', 'c', 'An End of Vd Treatment Visit is required for SVdX/SdX patients. See Table 3.', 'Confidential', 'Page 25', 'Version 4.0']\n\n###\n\n", "completion": "END"}